Trade groups have their say on EC's creation of HERA

18 November 2021

A couple of trade groups have had their say on the creation of the Health Emergency preparedness and Response Authority (HERA) to make Europe more ready to respond to future pandemics and other threats.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) and Vaccines Europe (VE) are confident that creating HERA is a first step to putting the continent on the front foot in addressing global health threats.

But they have issued a statement on various issues which they believe require particular attention during planning and implementation of preparedness, as well as response activities by HERA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK